These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 18511706)
1. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Mak A; Thomas A; Del Granado M; Zaleskis R; Mouzafarova N; Menzies D Am J Respir Crit Care Med; 2008 Aug; 178(3):306-12. PubMed ID: 18511706 [TBL] [Abstract][Full Text] [Related]
2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related]
3. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases. Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008 [TBL] [Abstract][Full Text] [Related]
4. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Lan NTN ; Lademarco MF; Binkin NJ; Tung LB; Quy HT; Cĵ NV Int J Tuberc Lung Dis; 2001 Jun; 5(6):575-8. PubMed ID: 11409587 [TBL] [Abstract][Full Text] [Related]
5. Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area. Schreiber YS; Herrera AF; Wilson D; Wallengren K; Draper R; Muller J; Dawood H; Doucette S; Cameron DW; Alvarez GG Int J Tuberc Lung Dis; 2009 Oct; 13(10):1274-80. PubMed ID: 19793433 [TBL] [Abstract][Full Text] [Related]
6. Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. Oxlade O; Schwartzman K; Pai M; Heymann J; Benedetti A; Royce S; Menzies D Eur Respir J; 2010 Oct; 36(4):870-7. PubMed ID: 20351030 [TBL] [Abstract][Full Text] [Related]
7. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087 [TBL] [Abstract][Full Text] [Related]
8. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Li J; Munsiff SS; Driver CR; Sackoff J Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767 [TBL] [Abstract][Full Text] [Related]
9. National anti-tuberculosis drug resistance study in Tanzania. Chonde TM; Basra D; Mfinanga SG; Range N; Lwilla F; Shirima RP; van Deun A; Zignol M; Cobelens FG; Egwaga SM; van Leth F Int J Tuberc Lung Dis; 2010 Aug; 14(8):967-72. PubMed ID: 20626940 [TBL] [Abstract][Full Text] [Related]
10. HIV infection and multidrug-resistant tuberculosis: the perfect storm. Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830 [TBL] [Abstract][Full Text] [Related]
11. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Yoshiyama T; Yanai H; Rhiengtong D; Palittapongarnpim P; Nampaisan O; Supawitkul S; Uthaivorawit W; Mori T Int J Tuberc Lung Dis; 2004 Jan; 8(1):31-8. PubMed ID: 14974743 [TBL] [Abstract][Full Text] [Related]
13. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Espinal MA; Laserson K; Camacho M; Fusheng Z; Kim SJ; Tlali RE; Smith I; Suarez P; Antunes ML; George AG; Martin-Casabona N; Simelane P; Weyer K; Binkin N; Raviglione MC Int J Tuberc Lung Dis; 2001 Oct; 5(10):887-93. PubMed ID: 11605880 [TBL] [Abstract][Full Text] [Related]
14. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Rodriguez M; Monedero I; Caminero JA; Encarnación M; Dominguez Y; Acosta I; Muñoz E; Camilo E; Martinez-Selmo S; de los Santos S; del Granado M; Casals M; Cayla J; Marcelino B Int J Tuberc Lung Dis; 2013 Apr; 17(4):520-5. PubMed ID: 23485386 [TBL] [Abstract][Full Text] [Related]
15. New treatment options for multidrug-resistant tuberculosis. Field SK; Fisher D; Jarand JM; Cowie RL Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676 [TBL] [Abstract][Full Text] [Related]
16. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru. Timperi R; Han LL; Sloutsky A; Becerra MC; Nardell EA; Salazar JJ; Smith-Fawzi MC Int J Tuberc Lung Dis; 2005 Feb; 9(2):175-80. PubMed ID: 15732737 [TBL] [Abstract][Full Text] [Related]
17. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Traore H; Fissette K; Bastian I; Devleeschouwer M; Portaels F Int J Tuberc Lung Dis; 2000 May; 4(5):481-4. PubMed ID: 10815743 [TBL] [Abstract][Full Text] [Related]
18. Screening outcomes from patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines. Gler MT; Guilatco RS; Guray CV; Tupasi TE Int J Tuberc Lung Dis; 2012 Oct; 16(10):1326-30. PubMed ID: 22863522 [TBL] [Abstract][Full Text] [Related]
20. Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital. Meskel DW; Abate G; Lakew M; Goshu S; Aseffa A Ethiop Med J; 2008 Jul; 46(3):219-25. PubMed ID: 19271385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]